Literature DB >> 1125673

Cellular and humoral immunity to hepatitis-B surface antigen in active chronic hepatitis.

W M Lee, W D Reed, C G Mitchell, R M Galbraith, A L Eddleston, A J Zuckerman, R Williams.   

Abstract

The hepatitis-B surface antigen (HBsAG) may be persistently present in the serum in a few cases of active chronic hepatitis but the cause of the disease in most patients is unknown. In a study of 39 HBsAg-negative cases cell-mediated immunity to HBsAg was observed in 24 (62%), suggesting a high frequency of previous infection with the hepatitis-B virus. Hepatitis-B surface antibody was detectable by radioimmunoassay in six patients, in all of whom complexes of HBsAg were present in the serum on electron microscopy. Out of 12 patients with HBsAg-positive active chronic hepatitis who were also studied eight, including all those untreated at the time, showed a cellular response to the antigen. Evidence of sensitization to a liver-specific cell surface lipoprotein was found with similar frequency in the two groups. These results are consistent with the hypothesis that hepatitis-B virus infection is important in initiating the disease in many cases of active chronic hepatitis and that sensitization to the liver cell membrane antigen is the autoimmune process responsible for the perpetuation of the liver injury.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1125673      PMCID: PMC1672762          DOI: 10.1136/bmj.1.5960.705

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis.

Authors:  A D Thomson; M A Cochrane; I G McFarlane; A L Eddleston; R Williams
Journal:  Nature       Date:  1974-12-20       Impact factor: 49.962

2.  Exposure and immunity to hepatitis-B virus in a liver unit.

Authors:  W D Reed; C G Mitchell; A L Eddleston; W M Lee; R Williams; A J Zuckerman
Journal:  Lancet       Date:  1974-04-06       Impact factor: 79.321

3.  Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain.

Authors:  W D Reed; R B Stern; A L Eddleston; R Williams; A J Zuckerman; A Bowes; P M Earl
Journal:  Lancet       Date:  1973-09-29       Impact factor: 79.321

4.  Cellular immunity and hepatitis-associated, Australia antigen liver disease.

Authors:  F J Dudley; R A Fox; S Sherlock
Journal:  Lancet       Date:  1972-04-01       Impact factor: 79.321

Review 5.  Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity.

Authors:  A C Allison; A M Denman; R D Barnes
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

6.  Evaluation of the leucocyte migration test as a measure of delayed hypersensitivty in man. Suppression of migration inhibition by puromycin.

Authors:  C G Mitchell; M G Smith; P L Golding; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1972-08       Impact factor: 4.330

7.  Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis.

Authors:  A L Eddleston; R Williams
Journal:  Lancet       Date:  1974-12-28       Impact factor: 79.321

8.  Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis.

Authors:  J Miller; M G Smith; C G Mitchell; W D Reed; A L Eddleston; R Williams
Journal:  Lancet       Date:  1972-08-12       Impact factor: 79.321

  8 in total
  23 in total

Review 1.  Immunological aspects of liver disease.

Authors:  A L Eddleston; P T Donaldson; J E Hegarty; B D Reed
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 2.  Chronic active hepatitis.

Authors:  P J Johnson; I G McFarlane
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 3.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  T lymphocyte-mediated cytotoxicity in HBsAg-positive liver disease.

Authors:  N El Sheikh; C G Osman; H Cullens; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

5.  HBsAg-negative chronic active hepatitis related to hepatitis B virus.

Authors:  A Goudeau; P Coursaget; J Drucker; P Maupas; P Borie; J P Benhamou
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

6.  T-lymphocyte cytotoxicity to HBsAg-coated target cells in hepatitis b virus infection.

Authors:  A Alberti; G Realdi; F Bortolotti; A M Rigoli
Journal:  Gut       Date:  1977-12       Impact factor: 23.059

7.  Diminished active T rosette levels and increased spontaneous B lymphocyte blastogenesis in hepatitis B virus positive chronic active hepatitis.

Authors:  G Budillon; G Scala; C D'Onofrio; S Cassano; F De Ritis
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

8.  Detection of HBSAG in fixed liver tissue - use of a modified immunofluorescent technique and comparison with histochemical methods.

Authors:  B Portmann; R M Galbraith; A L Eddleston; A J Zuckerman; R Williams
Journal:  Gut       Date:  1976-01       Impact factor: 23.059

9.  LM-Ag and LSP--two different target antigens involved in the immunopathogenesis of chronic active hepatitis?

Authors:  K H Meyer zum Büschenfelde; M Manns; T H Hütteroth; U Hopf; W Arnold
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

10.  Immunosuppressive treatment of chronic HBsAg-positive hepatitis in childhood.

Authors:  P Tolentino; C Jannuzzi; R Giacchino
Journal:  Infection       Date:  1983 Sep-Oct       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.